OncoMatch/Clinical Trials/NCT07246564
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Is NCT07246564 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Rozanolixizumab for myasthenia gravis.
Treatment: Rozanolixizumab — The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA II, MGFA III, MGFA IV (MGFA Clinical Classification)
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening Visit
Prior therapy
Cannot have received: anti-neonatal Fc receptor medication (rozanolixizumab)
previously received rozanolixizumab drug product
Cannot have received: immunosuppressants, biologics, and other therapies
treated with prohibited immunosuppressants, biologics, and other therapies within the timeframe shorter than the treatment-free period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify